Navigation Links
First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
Date:12/7/2008

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), was associated with an improvement in hematologic parameters in a limited number of patients with two other rare and severe complement-mediated diseases treated outside of a clinical trial, according to patient cases presented today at the 50th Annual Meeting of the American Society of Hematology (ASH).

Physicians reported on the first clinical experience with Soliris in patients with atypical Hemolytic Uremic Syndrome (aHUS) and Cold Agglutinin Disease (CAD), two rare and serious diseases. Like patients with PNH, patients with aHUS are missing or have defective complement inhibitors that help to regulate the body's immune system. These patients suffer from hemolysis, blood clotting which can be measured in part as reduced number of circulating platelets, and kidney damage. In two patients with aHUS, Soliris administration was associated with improvements in platelet levels and reduction in hemolysis. Patients with CAD suffer from an autoimmune attack on their red blood cells leading to severe complement activation and hemolysis (destruction of those blood cells), anemia, and poor quality of life. In one patient with CAD, Soliris treatment was associated with reduced hemolysis, absence of the need for blood transfusions and improved symptoms of fatigue and anemia. Eculizumab appeared to be well tolerated in these patients, with safety observations that were consistent with those reported from controlled trials in patients with PNH.

"We are encouraged by this initial clinical experience with eculizumab in a very limited number of aHUS and CAD patients. These observations and other knowledge of
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
4. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test
7. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
8. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
11. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Tenn. , July 22, 2014 Cumberland ... release second quarter 2014 financial results after the market ... and live Internet webcast will be held on Tuesday, ... discuss the results. To participate in the ... (for international callers).  A rebroadcast of the teleconference will ...
(Date:7/22/2014)... 22, 2014 The National Space Biomedical Research ... for Space Radiation Research (CSRR) under the leadership of ... Associate Professor of Pharmaceutical Sciences within the University of ... of Radiation Health. She is located in ... team of investigators working across four U.S. institutions, to ...
(Date:7/22/2014)... BURLINGTON, Mass. , July 22, 2014  Decision Resources ... in Canada will remain relatively stagnant ... is despite the fact that percutaneous coronary intervention (PCI) volumes ... to other developed markets, such as the United ... growth will be largely driven by the increase in penetration ...
Breaking Medicine Technology:Cumberland Pharmaceuticals To Announce Second Quarter 2014 Financial Results On August 5, 2014 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 2Boerma Led UAMS Team to Establish NSBRI's Center for Space Radiation Research (CSRR) 3The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 2The Canadian Interventional Cardiology Device Market Will Remain Relatively Stagnant Through 2022 at Around $80 Million 3
... Statistically Significant Clinical Results for,SB-509 in Development ... 22, 2007 /PRNewswire-FirstCall/ -- Sangamo,BioSciences, Inc. announced ... data from its ZFP Therapeutic(TM) program at ... Association,(ADA). As disclosed in an oral presentation ...
... 2007--Gilead,Sciences, Inc. (Nasdaq:GILD) today announced that Study ... company's once-daily,anti-HIV drug Viread(R) (tenofovir disoproxil fumarate ... treatment for chronic hepatitis B virus,(HBV) infection, ... show,that Viread is non-inferior to the company's ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1 ZFP,Therapeutic Data at American Diabetes Association Meeting 9Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6
(Date:7/22/2014)... of Hematology (ASH) will present the Society,s highest honor, ... in Hematology, to Kanti R. Rai, MD, of the ... for his 50-year career combining landmark clinical leukemia research, ... care. , The Wallace H. Coulter Award for ... who has been a vital contributor to the field ...
(Date:7/22/2014)... WASHINGTON -- Autoimmune disorders may share certain pathogenic mechanisms ... Washington University (GW) researcher Linda Kusner, Ph.D. , ... , This paradigm shifting work shows that the very ... are also expressed in cells that produce autoimmune diseases. ... of Neurology at the GW School of Medicine and ...
(Date:7/22/2014)... 2014 Ticket Down is a reliable ... at Fedex Field in Landover, MD. There has never been ... of international soccer. After the success of the American national soccer ... alive and well. One way that fans of the world’s sport ... with the 2014 Guinness International Champions Cup. The tournament will kick ...
(Date:7/22/2014)... The market for botulinum neurotoxin (BoNT) products has ... novel medical indications created and due to more cosmetic ... physical appearance is extremely valued. Although the BoNT market ... companies and technologies are setting ground for biosuperiors and ... price of 1st-gen products under pressure, only innovation is ...
(Date:7/22/2014)... French . ... to step out for a cigarette twice as often as ... those who have the hardest time shaking off the habit ... aware of. , Those insights were among the collective findings ... by a team of researchers based in part at ...
Breaking Medicine News(10 mins):Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Extra exercise helps depressed smokers kick the habit faster 2
... follicles, mouse study shows , , WEDNESDAY, Nov. 21 (HealthDay ... which a mother,s smoking before and after pregnancy might ... , Cigarette smoking during pregnancy has been shown in ... offspring, but this is the first study to offer ...
... Alberta, Nov. 21 What would you do if ... Beel ate properly,never smoked, wasn,t a drinker, exercised and ... young age of 32, he suffered a stroke. In ... a Brain Injury",(published by AuthorHouse -- http://www.authorhouse.com ), ...
... release and,statements are attributed to The American Liver ... to raising awareness,and improving the quality of life ... a statement today expressing its concern over the ... made repeated,use of medicine vials intended for single-patient ...
... about losing employment, survey found , WEDNESDAY, Nov. 21 (HealthDay ... levels of job-related stress, a new study shows. , A ... 1,544 people ages 53 to 85 who worked at least ... over half were male, 87 percent were white, about 8 ...
... body of knowledge to Texas,research center in Fort ... The University of,North Texas Health Science Center [ ... added several new members to its faculty,to build ... manipulative medicine., Anuja Ghorpade has joined the ...
... and Abbott Employees Give More Than $7.2 Million and ... in Communities Across the Country, ABBOTT PARK, Ill., ... out to help their neighbors, providing more than,$7.2 million ... across the country. These employee contributions from the,company,s annual ...
Cached Medicine News:Health News:Smoking Before, After Pregnancy Harms Daughters' Fertility 2Health News:Smoking Before, After Pregnancy Harms Daughters' Fertility 3Health News:Smoking Before, After Pregnancy Harms Daughters' Fertility 4Health News:The Blessing of a Brain Injury: Author Survives Injury to Brain Following Stroke, Uses Injury as Fuel to Overcome Odds 2Health News:The American Liver Foundation Encourages Heightened Awareness of Hepatitis B and C in Light of Recent Events in the News 2Health News:Jobs Don't Stress Most Older Workers 2Health News:UNT Health Science Center Appoints Eight New Faculty Members 2Health News:UNT Health Science Center Appoints Eight New Faculty Members 3Health News:Abbott Employees Give Back to Local Communities This Holiday Season 2Health News:Abbott Employees Give Back to Local Communities This Holiday Season 3
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... LactoSorb® No-Profile Screw and Washer ... for multiple soft tissue re-attachments ... No-Profile Screw and washer provides ... a standard screw and washer ...
... The Stryker Inter-Lock™ System ... surgery at the tibial fixation ... backup fixation into one implant. ... and can be used routinely ...
The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissu...
Medicine Products: